Publication number: 20240066132
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
Type:
Application
Filed:
July 14, 2023
Publication date:
February 29, 2024
Inventors:
David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
Publication number: 20210000964
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
Type:
Application
Filed:
June 1, 2020
Publication date:
January 7, 2021
Inventors:
David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
Publication number: 20180326079
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
Type:
Application
Filed:
May 21, 2018
Publication date:
November 15, 2018
Inventors:
David Weninger BARNES, Avirup BOSE, Alexandra Marshall BRUCE, Alokesh DUTTAROY, Chikwendu IBEBUNJO, Aaron KANTER, Louise Clare KIRMAN, Changgang LOU, Aimee Richardson USERA, Ken YAMADA, Jun YUAN, Frederic ZECRI
Publication number: 20160030585
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders.
Type:
Application
Filed:
June 12, 2015
Publication date:
February 4, 2016
Applicant:
NOVARTIS AG
Inventors:
David Weninger BARNES, Ken YAMADA, Chikwendu IBEBUNJO, Alokesh DUTTAROY, Louis Clare KIRMAN, Alexandra Marshall BRUCE, Aimee Richardson USERA, Frederic ZECRI, Jun YUAN, Changgang LOU, Aaron KANTER, Avirup BOSE